What is it?
Placental Growth Factor (PlGF) based testing is a simple blood test that quickly predicts the risk of pre-eclampsia so that pregnant women receive the most appropriate care.
If the test rules-out pre-eclampsia then this can lead to a reduction in monitoring and pregnant women can often return home quicker and spend less time in hospital.
Evidence has shown the test can be a better predictor of pregnancy outcome than standard of care tests.
Through its Maternity Network steering group the Oxford Academic Health Science Network (AHSN) is supporting the implementation of the PlGF test as a patient safety initiative. Three hospitals in the Oxford AHSN region have now decided to adopt an sFlt-1:PlGF test pathway with support from the Oxford AHSN. All other partner hospitals in the region have acknowledged the benefits of adopting a new pre-eclampsia pathway and are at various stages in business case development.
What are the benefits?
- Reduced demand on maternity services
- Improved patient safety through faster and accurate diagnosis
- Potential to reduce admissions for suspected pre-eclampsia
- Improved patient experience; reducing anxiety and hospital admissions
- Reduced demand on community midwives through reduction in follow-up
- Reduced inpatient monitoring tests
Where to start?
- NICE have produced an adoption support resource with insights from the NHS to get started.
- Follow the link to discover more about PlGF-based testing at the Royal United Hospital Bath NHS Foundation Trust (RUH)
- NICE Guidance: Diagnostic Guidance DG23 and Hypertension in pregnancy: diagnosis and management guidelines NG133
- NHS England Innovation and Technology Payment
- AHSN Innovation and Technology Payment: PlGF-based testing
- NICE Approved Supplier: Roche and Quidel
- Email: firstname.lastname@example.org
- AHSN lead: Oxford AHSN